Navigation Links
IRIDEX Reports First Quarter 2008 Financial Results
Date:5/13/2008

MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter of 2008 ended March 29, 2008.

Revenue for the first quarter of 2008 was $11.5 million, an 8.7% decrease from the $12.6 million reported for the first quarter of 2007. The Company's net loss was $0.9 million or $0.10 per diluted share for the first quarter of 2008 compared with a net loss of $4.9 million or $0.61 per diluted share in the first quarter of 2007. The prior year financial results do include the AMS/Laserscope aesthetics acquisition, which was completed on January 16, 2007.

Ophthalmology revenues were $7.5 million in the first quarter of 2008 compared with $7.2 million in 2007, an increase of 4.8%. Domestic ophthalmology revenues increased 10.6% to $4.4 million. International ophthalmology revenues decreased 2.4% to $3.1 million. Ophthalmology recurring revenues, consisting of disposable products and service, represented 55.2% of our total ophthalmology revenues for the first 3 months in 2008 and 55.5% for the comparable period in 2007.

Total aesthetics revenues were $3.9 million in the first quarter of 2008 compared with $5.4 million in the comparable period of 2007, a decrease of 26.8%. In the first quarter 2008 domestic aesthetics revenues decreased $1.2 million to $1.5 million and international aesthetics revenues decreased $0.3 million to $2.4 million.

Gross profit for the first quarter of 2008 was $4.8 million, compared with $5.2 million for the first quarter of 2007. Gross margins were 41.9% and 41.5%, respectively. Operating expenses for the first quarter 2008 were $5.5 million compared with $10.0 million for 2007.

Mr. Theodore A. Boutacoff, P
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. IRIDEX Announces Closing of $5.0 Million Private Placement
2. William Moore Appointed to IRIDEX Board of Directors
3. IRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor
4. James B. Hawkins Appointed to IRIDEX Board of Directors
5. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
6. IRIDEX Announces Third Quarter 2007 Conference Call and Release Date
7. IRIDEX Reports Third Quarter Financial Results
8. IRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date
9. IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
10. IRIDEX Announces First Quarter 2008 Conference Call and Release Date
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
...dical, Inc.(TM), a leading medical technology comp...heral vascular disease, has completed the first hu...rossBoss(TM) CTO Catheter and Stingray(TM) CTO Re-... the treatment of completely blocked arteries know...
...rency firm change:healthcare has a prescription th...healthcare and financial distress. , ...9 -- The disappearance of 3.6 million jobs since D...the unpredictable cost of medical care can not onl...
...ties more supportive of stem cell research funding... A new national study conducted among 962 physicia... supportive of stem cell research than consumers a...e than half (55%) reported that they agree with fe...
...revention has improved, mortality rates are down, ...irculation from the Framingham Heart Study, which...nce in 9824 men and women over four decades, has p...d that over the past 40 years rates of AMI diagnos...
..., Inc. (OTC Bulletin Board: EMED), a leading provi...he Medical and Dental industries, has signed a con...l solutions to AmeriPlan(R) Corporation,s national... drugs, chiropractic, podiatry, medical, hospital ...
...l Alliance on Mental Illness (NAMI) Michigan relea...e state of mental health care in our state. The S...e in its rating . Fourteen states improved their g... further this year," said Sherri Solomon, Executiv...
Other Medicine News:Health News:BridgePoint Medical Completes First U.S. Clinical Case Using CrossBoss and Stingray Devices in CTO Angioplasty Procedure 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 3Health News:Docs More Supportive of Stem Cell Research Funding Than Consumers After Viewing President's Speech 2Health News:Docs More Supportive of Stem Cell Research Funding Than Consumers After Viewing President's Speech 3Health News:Explaining trends in heart attack 2Health News:MedCom Signs National Provider Contract With AmeriPlan Corporation 2Health News:MedCom Signs National Provider Contract With AmeriPlan Corporation 3Health News:Michigan's Mental Health Care System Gets a D Grade in Latest Study 2
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Childbirth May Slow Progression of Multiple Sclerosis 62015 1Childbirth May Slow Progression of Multiple Sclerosis 62015 2Childbirth May Slow Progression of Multiple Sclerosis 62015 3DNA Genotek Launches Global Partner Program 14953 1DNA Genotek Launches Global Partner Program 14953 2DNA Genotek Launches Global Partner Program 14953 3Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 1Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 2Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 3
... Company to Submit a Supplemental New Drug Applica..., Pa., April 6 Cephalon, Inc . (Nasdaq: CEPH )...ee clinical trial of NUVIGIL(R) (armodafinil) Tabl... associated with jet lag disorder. Based on these...w Drug Application with the U.S. Food and Drug Adm...
...pril 3 Torax Medical Inc., a medical device compa...gastroesophageal reflux disease (GERD) has commenc... Management System. The trial, which is being con...centers in the U.S. and Europe, will evaluate the ...ients suffering from GERD despite medical therapy....
Other Medicine Technology:Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 3Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 4Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment 2
New Image Cut-to-Fit Convex FlexWear Skin Barrier
New Image Closed Mini Pouch
CenterPointLock Stoma Irrigator Drain
CenterPointLock Sterile Drainable Kits
Medicine Products: